

Ayuda Sinergias AECC 2025

Adjudicaciones

Dra. Eleonora Lapi
Centro Nacional Investigaciones
Oncológicas (CNIO)

Dissecting tumor cell–smooth muscle
crosstalk to understand the muscle-
invasive step of tumor progression

Dra. Aranzazu Villasante
Instituto de Bioingeniería de Cataluña
(IBEC)

Development and characterization of next-
generation nanobodies targeting pediatric
tumors using bioengineered models

Dr. Jorge Barbazán
Instituto de Investigación Sanitaria de
Santiago (IDIS)

MatrixRAD: Unveiling the impact of
advanced radiation modalities in the
control of tissue fibrosis and therapy
response in pancreatic cancer

Dr. Miguel Ruiz
Instituto de investigación Hospital 12
de octubre (i+12)

Utilizing Connexin43 to sensitize Small Cell
Lung Cancer to DNA Damage inducing
agents

Dra. Lucía Sanjurjo
Instituto de Investigación Sanitaria de
Santiago (IDIS)

NANO-BIT: Nanocarrier-based anti-BCL6
Intracellular antibody Therapy for
lymphoma

Dra. Sara Manzano
Instituto de Investigación Sanitaria
Biogipuzkoa (IIS Biogipuzkoa)

Oncostatin M signalling as a potential
suppressor of T-cell response in
metastatic breast cancer (ONCOSTA-T
MET)

Dra. Beatriz Soldevilla
Instituto de investigación Hospital 12
de octubre (i+12)

Hacking the Neuroendocrine Tumors
(NETs): Osteopontin and Its Role in the
Tumoral Microenvironment of NETs

Dra. Natalia Sanz
Instituto de Investigaciones
Biomédicas Sols-Morreale IIBM (CSIC-
UAM)

Unraveling the connection between
Whole Genome Doubling and the 11q13
Amplicon in Head and Neck Cancer:
Biomarkers for Prognosis and Therapy

Dr. Julio José Jiménez
Cancer Center Clínica Universidad de
Navarra (CIMA-CCUN)

Exploiting KRAS inhibitors-induced
metabolic rewiring to enhance antitumor
activity against pancreatic cancer

Dra. Josefa Antonia Quiroz
Centro de Tecnología Biomédica
(CTB-UPM)

Is the PEDF protein responsible (or one of
the factors responsible) for the anticancer
effect of the growing deer antler extract?

Suplentes

Dr. Gabriel Ortega
Centro de Investigación
Cooperativa en Biociencias (CIC
bioGUNE)

SMARTherapy: antibody-based Sensor
for Monitoring Adverse Reactions in
immunotherapy

Dra. Valeria Tubita
Vall d'Hebron Instituto de
Investigación (VHIR)

Preclinical study of the combination of
anti-HER2 therapies and PARP inhibitors
in HRD-HER2 positive Endometrial
Cancer

Dr. Cristian Suárez
Centro de Investigaciones
Energéticas, Medioambientales y
Tecnológicas (CIEMAT)

Extracellular Vesicles for targeted
radiolotope Transport in Advanced
bladder cancer diagnosis and therapy
(acronym: EVITA)